Background: The prevalence of lung cancer is 14% among the newly diagnosed cancer cases worldwide.
Currently, the number of drugs that are in clinical practice is having a high prevalence of side effect and
multidrug resistance. Researchers have made an attempt to expand a suitable anticancer drug that has no MDR
and side effect.
Objective: Extensive exploration of Coumarin derivatives as a potent inhibitor of variety of proteins including
EGFR, tyrosine kinase, ERK1/2, PI3K, HSP 90, Bax, STAT proteins, NF-κB and telomerase which have been
associated with lung cancer.
Method: The recent literature was surveyed utilizing the online resources and databases including scifinder,
pubchem, EMBL, scopus and google scholar.
Results: Upon analyzing the structure-activity relationship, it was found that N-aryl carboxamide, phenyl substitution
at the C-3 position and 1,2,3- triazolyl, trihydroxystilbene, amino substitution at the C-4 position of the
coumarin nucleus were the most effective in targeting lung cancer.
Conclusion: This review is a collaborative and extensive compilation of synthetic strategies, mechanism of
action, and the structure-activity relationship thereof for the management of lung carcinoma.